MANENYSEPharmaceutical PreparationsUS GAAP · USD

Veradermics, Inc

Veradermics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing dermatology product candidates. Its lead program, VDPHL01, is being developed for commercialization in the United States, with the company also considering future licensing or collaboration arrangements in foreign territories.

Ask about the company
Operating profit (EBIT)-72.3m USD
−170.2 %y/y
Net income-70.0m USD
−164.3 %y/y
Free cash flow-71.6m USD
−202.4 %y/y

Fiscal year 2025 · change from previous year

Development 2024–2025

-80-60-40-200m USD2024: EBIT -27 m USD20242025: EBIT -72 m USD2025-72
RevenueOperating profit (EBIT)
Ask Clarifo about Veradermics, Inc

Business

Share of revenue
Lead product candidate100 %

VDPHL01 and related dermatology product candidates under development.

Customers

Veradermics is developing products for dermatologists, physicians, and ultimately patients in the dermatology and medical aesthetics markets. Its near-term commercial model is oriented toward cash-pay consumers rather than reimbursed healthcare channels, so demand depends on direct patient willingness to pay and physician adoption.

Dermatologists and physicians

Medical professionals who must be educated on the product's benefits and support adoption.

Cash-pay patients

End consumers who directly purchase the product if approved, without third-party reimbursement.

Direct-to-consumer audience

Prospective users reached through social media, email, text, and influencer marketing.

Foreign commercial partners

Potential licensing or collaboration partners for commercialization outside the U.S.

Strategy

Veradermics is focused on advancing VDPHL01 through clinical development, regulatory review, and pre-commercial preparation. The company is also building the sales, marketing, and distribution capabilities needed for a cash-pay launch, while keeping open the option to use third-party partners in foreign markets.

Advance the lead dermatology programShort term

Clinical progress and regulatory approval are required before any product revenue can begin.

Prepare for cash-pay commercializationShort term

The business model depends on direct consumer sales rather than reimbursement.

Expand commercial reach through partnershipsMedium term

Foreign licensing can extend market access without building a full direct presence abroad.

Geography

The company is headquartered in the United States and currently expects initial commercialization activities to be centered there. Its disclosures also contemplate foreign territories through licensing or collaboration agreements, but those markets are not yet the core operating base.

Risks

Veradermics faces the typical risks of a clinical-stage biopharmaceutical company: product candidates may fail in development, approval may be delayed or denied, and commercialization may never produce meaningful revenue. Because its planned launch model is cash-pay and consumer-driven, demand is exposed to discretionary spending, marketing effectiveness, reimbursement uncertainty, and regulatory scrutiny of direct-to-consumer advertising.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development and regulatory failure1Cash-pay demand volatility2Capital dependence3Intellectual property competition4Direct-to-consumer marketing restrictions5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development and regulatory failureImpact: CriticalLikelihood: High

    Product candidates may not complete trials successfully or obtain approval, preventing commercialization.

    Exposure: VDPHL01 and other pipeline assets

  2. Cash-pay demand volatilityImpact: HighLikelihood: High

    Sales depend on discretionary consumer spending and aesthetics-related purchasing behavior.

    Exposure: Planned U.S. launch market

  3. Capital dependenceImpact: HighLikelihood: High

    The company expects continued losses and will need additional funding to support operations.

    Exposure: Corporate funding and development spend

  4. Intellectual property competitionImpact: HighLikelihood: Medium

    Patent challenges or third-party patents could reduce protection and market exclusivity.

    Exposure: Pipeline and future product candidates

  5. Direct-to-consumer marketing restrictionsImpact: MediumLikelihood: Low

    FDA oversight of digital and social media drug advertising may limit customer acquisition tactics.

    ExposureSocial mediaEmailTextInfluencer marketing
Ask Clarifo about Veradermics, Inc

Accounting

Judgemental items
Research and development accruals

Clinical trial and vendor costs are estimated before invoices are finalized, affecting expense timing and liabilities.

Impact: Can move quarterly operating loss and accrued expenses

Stock-based compensation valuation

Expense depends on assumptions such as fair value, volatility, and expected term.

Impact: Can materially affect reported G&A and R&D expense

Fair value of common stock

Used in valuing equity awards and can change sharply around financing and IPO events.

Impact: Affects compensation expense and equity measurements

Pre-commercial, pre-revenue expense recognition

With no product sales, operating results are driven almost entirely by development and launch spending.

Impact: Losses are highly sensitive to timing of clinical and launch activities

Similar listed companies

Publicly listed companies with a comparable business focus.

Verrica Pharmaceuticals Inc.

VRCA · Pharmaceutical Preparations

Edesa Biotech, Inc.

EDSA · Pharmaceutical Preparations

Dyadic International, Inc

DYAI · Biological Products, (No Diagnostic Substances)

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Verastem, Inc.

VSTM · Pharmaceutical Preparations

Dermata Therapeutics, Inc.

DRMA · Pharmaceutical Preparations

Last updated: 24/09/2026